Esophageal Acidification During Nocturnal Acid-breakthrough with Ilaprazole Versus Omeprazole in Gastroesophageal Reflux Disease

被引:15
作者
Karyampudi, Arun [1 ]
Ghoshal, Uday C. [1 ]
Singh, Rajan [1 ]
Verma, Abhai [1 ]
Misra, Asha [1 ]
Saraswat, Vivek A. [1 ]
机构
[1] Sanjay Gandhi Postgrad Inst Med Sci SGPGIMS, Dept Gastroenterol, Lucknow, Uttar Pradesh, India
关键词
Chest pain; Electric impedance; Heartburn; Proton pump inhibitors; PROTON-PUMP INHIBITORS; HEALTHY-SUBJECTS; NORMAL VALUES; CLINICAL-IMPLICATIONS; CROSS-OVER; PH-METRY; IMPEDANCE; PHARMACOKINETICS; PHARMACODYNAMICS; ESOMEPRAZOLE;
D O I
10.5056/jnm16087
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims Though nocturnal acid-breakthrough (NAB) is common in gastroesophageal reflux disease (GERD) patients, its clinical importance results from esophageal acidification, which has been shown to be uncommon. Ilaprazole, a long-acting proton pump inhibitor, may cause NAB infrequently. Accordingly, we studied prospectively, (1) frequency and degree of esophageal acidification during NAB, and (2) frequency and severity of NAB while on ilaprazole versus omeprazole. Methods Fifty-eight consecutive patients with GERD on once daily ilaprazole, 10 mg (n = 28) or omeprazole, 20 mg (n = 30) for > one month underwent 24-hour impedance-pH monitoring prospectively. NAB was defined as intra-gastric pH < 4 for > one hour during night, and esophageal acidification as pH < 4 for any duration. Nocturnal symptoms (heartburn, regurgitation, and chest pain) were also recorded. Results Of the 58 patients (age 35.5 [inter-quartile range 26.5-46.0] years, 38 [65.5%], 42 (72.4%) had NAB. Though patients with NAB had lower nocturnal intra-gastric pH than without (2.8 [1.9-4.1] vs 5.7 [4.6-6.8], P < 0.001), frequency and duration of nocturnal esophageal acidification (17/42 vs 4/16, P = 0.360 and 0.0 [0.0-1.0] vs 0.0 [0.0-0.3] minutes, P = 0.260, respectively) and symptoms were comparable (13/42 vs 6/16, P = 0.750). Though ilaprazole was associated with less NABs (1 [range 1-2, n = 19] vs 1 [range 1-3, n = 23], P = 0.010) than omeprazole, the frequency, duration, and mean intra-gastric pH during NAB were comparable (19/28 vs 23/30, P = 0.560; 117 [0-315] vs 159 [69-287] minutes, P = 0.500; 1.02 [0.7-1.4] vs 1.04 [0.44-1.3], P = 0.620, respectively). Conclusions Though NAB was common while patients were on a proton pump inhibitor, esophageal acidification was uncommon. Frequency and severity of NAB were comparable among patients on ilaprazole and omeprazole, except for the lesser number of NABs with ilaprazole.
引用
收藏
页码:208 / 217
页数:10
相关论文
共 41 条
[1]   Gastric pH - the most relevant predictor of benefit in reflux disease? [J].
Armstrong, D .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 20 :19-26
[2]   CONCENTRATION OF REFLUXED ACID AND ESOPHAGEAL MUCOSAL INJURY [J].
BREMNER, RM ;
CROOKES, PF ;
DEMEESTER, TR ;
PETERS, JH ;
STEIN, HJ .
AMERICAN JOURNAL OF SURGERY, 1992, 164 (05) :522-527
[3]   Multivariate analysis of pathophysiological factors in reflux oesophagitis [J].
Cadiot, G ;
Bruhat, A ;
Rigaud, D ;
Coste, T ;
Vuagnat, A ;
Benyedder, Y ;
Vallot, T ;
LeGuludec, D ;
Mignon, M .
GUT, 1997, 40 (02) :167-174
[4]   Effect of CYP2C19 Genetic Polymorphism on Pharmacokinetics and Pharmacodynamics of a New Proton Pump Inhibitor, Ilaprazole [J].
Cho, Hoon ;
Choi, Min-Koo ;
Cho, Doo-Yeon ;
Yeo, Chang-Woo ;
Jeong, Hye-Eun ;
Shon, Ji-Hong ;
Lee, Jun-Yeoun ;
Shin, Jae-Soo ;
Cho, Mong ;
Kim, Dong-Yeon ;
Shin, Jae-Gook .
JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 52 (07) :976-984
[5]   Impedance pH Guided Approach to Proton Pump Inhibitor-refractory Non-erosive Reflux Disease [J].
Cho, Yu Kyung .
JOURNAL OF NEUROGASTROENTEROLOGY AND MOTILITY, 2014, 20 (04) :419-420
[6]   Twice-daily proton pump inhibitor therapy does not decrease the frequency of reflux episodes during nocturnal recumbency in patients with refractory GERD: analysis of 200 patients using multichannel intraluminal impedance-pH testing [J].
Clayton, S. B. ;
Rife, C. C. ;
Singh, E. R. ;
Kalbfleisch, J. H. ;
Castell, D. O. .
DISEASES OF THE ESOPHAGUS, 2012, 25 (08) :682-686
[7]   The pharmacokinetics of ilaprazole for gastro-esophageal reflux treatment [J].
de Bortoli, Nicola ;
Martinucci, Irene ;
Giacchino, Maria ;
Blandizzi, Corrado ;
Marchi, Santino ;
Savarino, Vincenzo ;
Savarino, Edoardo .
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2013, 9 (10) :1361-1369
[8]   Acid inhibition effect of ilaprazole on Helicobacter pylori-negative healthy volunteers: An open randomized cross-over study [J].
Du, Yi Qi ;
Guo, Wen Yuan ;
Zou, Duo Wu ;
Zhan, Xian Bao ;
Li, Zhen ;
Hu, Jin Hong ;
Gong, Yan Fang ;
He, Jia ;
Lu, Jian Ping ;
Li, Zhao Shen .
JOURNAL OF DIGESTIVE DISEASES, 2012, 13 (02) :113-119
[9]   Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough [J].
Fackler, WK ;
Ours, TM ;
Vaezi, MF ;
Richter, JE .
GASTROENTEROLOGY, 2002, 122 (03) :625-632
[10]   Relationship of severity of gastroesophageal reflux disease with gastric acid secretory profile and esophageal acid exposure during nocturnal acid breakthrough: A study using 24-h dual-channel pH-metry [J].
Ghoshal, Uday C. ;
Chourasia, Dipti ;
Tripathi, Shweta ;
Misra, Asha ;
Singh, Kartar .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2008, 43 (06) :654-661